BOLT
Bolt Biotherapeutics, Inc.
There isn't enough reported data to score BOLT yet.
BOLT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Unavailable | |
| Unavailable |
BOLT's revenue is currently healthy, but its profitability is weak. There isn't enough data to rate its cash flow and balance sheet.
BOLT PE Valuation
BOLT has no meaningful PE right now: it lost money over the past year.
BOLT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect BOLT's losses to shrink, with revenue declining.
BOLT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$16.47 | +$9.99 |
| Q1 2026 | -$16.36 | +$16.84 |
| Q4 2025 | -$17.85 | +$15.15 |
| Q3 2025 | -$22.18 | +$12.02 |
| Q2 2025 | -$26.46 | +$8.34 |
| Q1 2025 | -$33.20 | $0.00 |
| Q4 2024 | -$33.00 | +$3.60 |
| Q3 2024 | -$34.20 | +$3.60 |
BOLT is still losing money, but far less than before: $16.47 per share over the past year, against $59.40 at its worst in late 2021.
BOLT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $5K | -100% |
| Q1 2026 | $26K | -98% |
| Q3 2025 | $2.2M | +90% |
| Q2 2025 | $1.8M | +41% |
| Q1 2025 | $1.2M | -77% |
| Q3 2024 | $1.1M | -55% |
| Q2 2024 | $1.3M | -11% |
| Q1 2024 | $5.3M | +189% |
BOLT's revenue is growing: $5,000 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -167480% | -166970 points |
| Q1 2026 | -29235% | -28243 points |
| Q4 2025 | -283% | N/A |
| Q3 2025 | -355% | +1086 points |
| Q2 2025 | -511% | +1262 points |
| Q1 2025 | -991% | -667 points |
| Q3 2024 | -1441% | -722 points |
| Q2 2024 | -1772% | -388 points |
BOLT's operating margin was −167480% last quarter, down 166969 points from the same quarter a year ago, near the bottom of its range since 2019.
BOLT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$8M | +$5.3M |
| Q4 2025 | -$7.2M | +$7.3M |
| Q2 2025 | -$9.6M | +$6.5M |
| Q1 2025 | -$13.4M | +$3.4M |
| Q4 2024 | -$14.4M | -$159K |
| Q3 2024 | -$14M | +$2.9M |
| Q2 2024 | -$16.1M | -$998K |
| Q1 2024 | -$16.8M | +$6.7M |
BOLT has burned cash in almost every quarter: −$38M over the past year, against −$61M the year before.
BOLT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +10.1K shares |
| 1 year | -12% | -227K shares |
| 3 years | -10% | -197K shares |
| 5 years | -7.6% | -139K shares |
BOLT has 2M diluted shares, down 12% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
| Q3 2019 | — |
BOLT Net Leverage
BOLT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
BOLT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.2 | Neutral |
| Stochastic | 69.4 | Neutral |
BOLT's weekly RSI is 61 (neutral) and its Stochastic is 69 (neutral).
BOLT PE vs Healthcare Sector
BOLT has no meaningful PE right now: it lost money over the past year.
BOLT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.06 | 17% above |
| 20 week MA | $4.34 | 36% above |
| 50 week MA | $4.74 | 25% above |
| 100 week MA | $5.88 | 0.5% above |
| 200 week MA | $13.8 | 57% below |
BOLT has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 57% below its 200-week average.
BOLT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $643.0 | $94.6 | -85% |
| 2022 | $94.6 | $26.0 | -73% |
| 2023 | $26.0 | $22.4 | -14% |
| 2024 | $22.4 | $10.4 | -54% |
| 2025 | $10.4 | $5.33 | -49% |
| 2026 YTD | $5.33 | $5.91 | +11% |
BOLT has finished every year since 2021 lower, and it's up 11% so far in 2026.